

The Impact of Biosimilar Competition in Europe 2022

Prepared for European Commission (DG SANTE)

Per Troein, *VP*, *Strategic Partners* **Max Newton**, *Global Supplier & Association Relations*

© 2021. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.


≣IQVIA

Disclaimer:

This report has been prepared by IQVIA at the request of the European Commission services with initial contributions on defining the KPIs from EFPIA, Medicines for Europe, and EuropaBio.

The observations have been developed solely by IQVIA based on the data and analyses performed. The information and views set out in this report are those of its authors and are not to be attributed to, nor necessarily reflect the views of the European Commission or any of its services.

The European Medicines Agency (EMA) has a central role in setting the rules for biosimilar submissions, approving applications, establishing approved indications and monitoring adverse events, and if necessary, issuing safety warnings. We have, when appropriate, quoted their information and statements.




- + Introduction
- + Methodology and the Country & Therapy Area KPIs
- + IQVIA's 5 Observations in 2022
- + 10.10am 10.20am: Q&A session




The analysis builds on historic publications on biosimilars

Key observations on price, volume and market share since the arrival of biosimilars in Europe





3



- + Introduction
- + Methodology and the Country & Therapy Area KPIs
- + IQVIA's 5 Observations in 2022
- + Q&A



9 therapy classes with biosimilar competition are shown

The products are split into 4 categories based on regulatory and protection status

Therapy classes

- 1. Human Growth Hormone (HGH)
- 2. Granulocyte-colony Stimulating Factor (GCSFs)
- 3. Epoetin (EPO)
- 4. Anti-Tumour Necrosis Factor (Anti-TNFs)
- 5. Fertility (Follitropin Alfa)
- 6. Insulins
- 7. Oncology
- 8. Low-Molecular-Weight Heparin (LMWHs) Shown in for the 1st time in 2021

9. Ophthalmology

Shown in anticipation of biosimilar entry

Product categorisation

Description		Key	Other segmentation	
Biosimilar Medicinal Product: Product approval, demonstrating similarity to the Product in terms of quality characteristics safety and efficacy.	Reference Medicinal			
Referenced Medicinal Product: Original market exclusivity at the start of its life, expired, and the product has been categ having a biosimilar with an EMA-approve authorisation available on a European m	xclusivity has now prised as referenced by ed marketing		Accessible market	Total
Non-Referenced Medicinal Product: C market exclusivity at the start of its life, e expired*, and the product has never been Referenced Medicinal product by receivin marketing authorisation.	xclusivity has now n categorised as a			market: products within the same ATC3**
 Non-accessible category: products with as the accessible category products. The generation products; this category may in different dosing schedules and / or route those in the accessible category, and has 	ese are typically second- nclude products with of administration to		Non- accessible market	

*The Intellectual Property for biologicals can involve multiple patents and patent timelines for each individual product and therefore it is difficult to given an exact date for patent expiry for biologicals. It should be noted that these results are estimates as determined from IQVIA MIDAS and ARK Patent Intelligence where available. ** ATC definitions: EPO = B3C0 (ERYTHROPOIETIN PRODUCTS); GCSFs = L3A1 (COLONY-STIMULATING FACT.); HGH = H4C0 (GROWTH HORMONES); ANTI-TNF = L4B0 (ANTI-TNF PRODUCTS); INSULIN = A10C 1,2,4,5,9; Oncology = L1G0 1,2,3,5,9 (RESTRICTED TO 3 major products with biosimilar competition); LMWHs = B1B2 (FRACTIONATED HEPARINS), Ophthalmology: S1PO (OCULAR ANTINEOVAS)



The report is continually adjusted to reflect new situations

Information for biosimilar stakeholders

Expanded data period

 In 2022, full-year 2022 data plus June MAT 2022 data to remain up to date

Stricter definitions

- Restricting the definition of 'referenced' to reflect biosimilar EMA-MA prior to LOE
- Protection status was not explicitly highlighted
- Historic recategorization

Ophthalmology

50.000

Monoclonal Antibody Antineoplastic agents use monoclonal antibodies (mAb) to bind monospecifically to certain cells or proteins to treat ocular inflammatory diseases. The objective is that this treatment will stimulate the patient's immune system to attack those cells.

Eylea (aflibercept) and Lucentis (ranibizumab) are anti-VEGF agents used to treat several ocular inflammatory conditions, including wet age-related macular degeneration (AMD), macular edema, and diabetic retinopathy. They work by preventing the growth of abnormal blood vessels in the eye caused by the VEGF protein. Availating (bevicziumab) is another anti-VEGF agent that is also used to treat inflammatory ocular diseases. However, considering that the primary indications used for bevacizumab biosimiliars are in Oncology, and since IQVIA sales and treatment day volume cannot be split by indication, bevacizumab market dynamics are only considered in this separate Oncology section, and not in the Ophthalmology section.


WHO DDD's are not available for products in this class, so the DDD's were calculated using EMA dosing information.



2013 2014 2015 2016 2017 2018 2019

referenced market in 2022: Not applicable enced medicines in 2022: Not applicable milars in 2022: Not applicable

34. The Impact of Biosimilar Competition in Europe



Imology approved indication

Granularity


- View historical status of products
- Delay to biosimilar entry
- Visibility to 2^{nd,} 3^{rd,} 4th...
 12-year history of the market

Larger scope

igvia.com | 35

- Ophthalmology included in full for the first time
- Oncology has been expanded further from rituximab, bevacizumab, and trastuzumab to include (currently) non-accessible biologics pertuzumab and combinations






- + Introduction
- + Methodology and the Country & Therapy Area KPIs
- + IQVIA's 5 Observations in 2022
- + 10.10am 10.20am: Q&A session



The biologic market is increasingly important


Biologics represent a large portion of current expenditure, making competition critical





The direct impact of COVID-19 has largely passed


Indirect impact on access to healthcare, diagnosis, and treatments are being minimised





EU savings from the impact of competition have reached >€30Bn

Cost has fallen for multiple years in a row while total volume has increased




Caveats: This figure is not equivalent to all savings. And is therefore an under-estimate. The data does not include the impact of rebates or discounts, which may have been present prior to the introduction of biosimilars in small quantities, and are highly significant post-biosimilar entry as it is based on publicly available list prices.. Source: IQVIA MIDASTM data from 2006 – 2022, using Euros at constant exchange rates; value includes all originator products with approved biosimilars from 2006 – 2022, covering the full European Economic Area (33 CTYs), calculated volume is in treatment days determined by WHO-DDD, and where values are unavailable via Oncology Dynamics Physician Survey (2017) DDD estimates. Volume is solely biosimilar treatment days



Access to biologics is increasing in all country, but not evenly


Countries which high growth start from a low base and are not catching up





The disparity between countries is increasing

Increasing the uptake of biosimilars is not enough to reduce the gap without considering the system




*Normalised to the year of first recorded biosimilar sales in each country, to account for markets that are delayed in using biosimilars after loss of patent protection Chart notes: Includes TD for all market segments (Non-accessible, Non-referenced, Referenced, Biosimilars); All countries are ranked based on TD/Capita at +6 years and the top-5 and bottom-5 countries includes in this analysis

12

High proportions of EU spending expect competitors


Competition within the major molecules is increasingly fierce





Not all molecules are attractive for competitors to enter


Biologic molecules do not necessarily support a biosimilar in the current system





Biologic LOEs are increasing, and research has already started

The number of molecules is higher, while average value is lower



- 2/3 of historic LOEs received biosimilar competition, due to molecule size and type
- More biologics will be losing protection that historically (+30)
- More biologics molecules have a competitor in development than before (+14)
- Not all future biologics will have competition, historically this has been ~1/3 of all molecules
- Multiple high value biologics losing exclusivity which explains the uptick in 2025
- Biologics with competitors development are already for products losing exclusivity in 2027

Source: IQVIA Patent Intelligence, Pipeline Intelligence, and IQVIA Forecast Link analysis (November 2022); Historic analysis sourced from IQVIA Institute


report, Protection expiry and Journey into the Market (2022) Note: The intellectual property for biologicals can involve multiple patents, patent timelines, data exclusivity, and litigation for each individual product and therefore it is difficult to give an exact date for protection expiry for biologicals. It should be noted that these results are estimates as determined from IQVIA MIDAS® and ARK Patent Intelligence where available, and historical products are cross-referenced to public sources



Observation 3: Access


Availability of recently launched biologics is low

Biosimilar entry is complex without originator access, and offers payers limited savings if unused



Source: Based on IQVIA W.A.I.T dataset and IQVIA HTA-Accelerator datasets covering novel active substances (NAS) molecules launched within 2014 – 2020 (November 2022 analysis), including all current EU members, EEA members, and countries considering ascension. Reimbursement defined by availability on a public reimbursement list in a country





- + Introduction
- + Methodology and the Country & Therapy Area KPIs
- + IQVIA's 5 Observations in 2022
- + 10.10am 10.20am: Q&A session





Thank you!

Contact us for further questions

Per Troein (<u>per.troein@iqvia.com</u>) Max Newton (<u>maximilian.newton@iqvia.com</u>)

The Impact of Biosimilar Competition in Europe 2022 www.iqvia.com/whitepapers €IQVIA

White Paper

The Impact of Biosimilar Competition in Europe December 2022

PER TROEIN, Vice President, Strategic Partners, IQVIA MAX NWTON, Ingagement Manager, Global Suppiler & Association Relations, IQVIA KELSEY STODDART, Consultant, Global Suppiler & Association Relations, IQVIA AURELIO ARLAS, Director, European Thought Leadership, IQVIA



© 2021. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.